Yahoo · Oct 26, 2026
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It
Organon (OGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
OG
NYSE · OGN
Organon & Co.
Healthcare · Drug Manufacturers - General
$13.84
Up+$0.03 (+0.22%)
Updated Nov 1, 2026, 5:26 PM
SID Score
5.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.91B
- P/E ratio
- 3.82
- Dividend yield
- 2.46%
- 52-week range
- $5.69 – $13.84
- Volume
- 1.85M
- Avg. volume
- 5.64M
Price performance · OGN
OGN price history
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
OGN closed at $13.84 after 20 trading sessions, up 1.02% for the selected period.
- Last close
- $13.84
- Period change
- +1.02%
- Period low
- $13.70
- Period high
- $13.84
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $13.83 | $13.84 | $13.805 | $13.84 | 1.85M |
| Oct 29, 2026 | $13.76 | $13.83 | $13.76 | $13.81 | 2.51M |
| Oct 28, 2026 | $13.75 | $13.78 | $13.75 | $13.78 | 3.16M |
| Oct 27, 2026 | $13.74 | $13.78 | $13.74 | $13.75 | 1.87M |
| Oct 26, 2026 | $13.75 | $13.76 | $13.74 | $13.74 | 1.55M |
| Oct 23, 2026 | $13.74 | $13.76 | $13.74 | $13.75 | 1.05M |
| Oct 22, 2026 | $13.75 | $13.76 | $13.74 | $13.75 | 2.55M |
| Oct 21, 2026 | $13.75 | $13.77 | $13.74 | $13.75 | 2.56M |
| Oct 20, 2026 | $13.75 | $13.80 | $13.74 | $13.76 | 2.55M |
| Oct 19, 2026 | $13.77 | $13.77 | $13.715 | $13.75 | 3.25M |
| Oct 16, 2026 | $13.77 | $13.78 | $13.74 | $13.76 | 2.65M |
| Oct 15, 2026 | $13.75 | $13.77 | $13.75 | $13.76 | 1.98M |
| Oct 14, 2026 | $13.77 | $13.77 | $13.74 | $13.74 | 1.81M |
| Oct 13, 2026 | $13.77 | $13.79 | $13.76 | $13.77 | 2.89M |
| Oct 12, 2026 | $13.80 | $13.80 | $13.76 | $13.77 | 932.35K |
| Oct 9, 2026 | $13.76 | $13.83 | $13.75 | $13.81 | 3.26M |
| Oct 8, 2026 | $13.78 | $13.80 | $13.75 | $13.75 | 2.09M |
| Oct 7, 2026 | $13.72 | $13.79 | $13.72 | $13.79 | 2.21M |
| Oct 6, 2026 | $13.74 | $13.75 | $13.73 | $13.74 | 1.95M |
| Oct 5, 2026 | $13.72 | $13.75 | $13.70 | $13.70 | 2.88M |
Latest OGN news
The latest Smart Investors Daily articles mentioning OGN.
Stock researchCompany · Overview
Company
Market Activity
Research & News
OGN research
Overview
Company profile and research snapshot.
Company profile
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $6.25
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Apr 29, 2026 | BNP Paribas | Neutral | — |
| Apr 28, 2026 | Piper Sandler | Neutral | — |
| Feb 24, 2026 | Barclays | Underweight | — |
| Dec 9, 2025 | Barclays | Underweight | — |
| Nov 11, 2025 | JP Morgan | Underweight | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 19, 2026
Organon to Report Third Quarter 2026 Results in Its Regularly Scheduled Form 10-Q Filing
JERSEY CITY, N.J., October 19, 2026--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its third quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission ("SEC"). The company also plans to disclose certain non-GAAP financial measures and their reconciliation to their comparable GAAP measures for the third quarter 2026, which will be
Yahoo · Oct 16, 2026
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
JERSEY CITY, N.J., October 16, 2026--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
Benzinga · Oct 16, 2026
Organon To Present Data From Its Current Phase 3 Trial Of MIUDELLA Intrauterine Device At 2026 Society Of Family Planning Annual Meeting
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced that Sebela Women’s Health will present interim results from an
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
